New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
11:04 EDTIMMUImmunomedics reports results from three IMMU-130 phase I trials
Immunomedics reported the results from 3 Phase I trials with IMMU-130, the company's investigational anti-CEACAM5 antibody conjugated to the irinotecan-metabolite, SN-38. The antibody-drug conjugate was therapeutically active in all 3 trials, but a more frequent dosing schedule, with administrations of IMMU-130 once or twice-weekly for 2 weeks followed by a week off, was more active in patients with metastatic colorectal cancer than when administered every other week. Results from these Phase I studies were presented at the 2014 Annual Meeting of the American Association for Cancer Research in San Diego, CA, by a group of clinical investigators. In all three trials, measurement of SN-38 concentrations in the serum found much higher levels that were sustained longer than is typically found with irinotecan therapy, the parental drug of SN-38. However, most of the SN-38 remains bound to the antibody, keeping it in an inactive form to normal tissues while in circulation, which reduces toxicity, yet allowing for higher concentrations of activated SN-38 to be delivered to the tumor where it is released from the pH- sensitive linker. Neutropenia and manageable diarrhea were the main side effects. "These results suggest that IMMU-130 may have a high therapeutic index and can be administered in repeated cycles in advanced mCRC patients," commented CEO Cynthia Sullivan.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
12:33 EDTIMMUImmunomedics upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
09:32 EDTIMMUImmunomedics granted breakthrough therapy designation for sacituzumab govitecan
Immunomedics announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease.
09:29 EDTIMMUImmunomedics granted Breakthrough Therapy Designation from FDA for IMMU-132
Subscribe for More Information
February 3, 2016
16:05 EDTIMMUImmunomedics sees Phase 3 PANCRIT-1 trial completing enrollment in 2016
Subscribe for More Information
16:03 EDTIMMUImmunomedics reports Q2 EPS (15c), two estimates (14c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use